title: Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation.
abstract: Whereas alpidem is hepatotoxic, zolpidem is not. Despite closely related chemical structures, alpidem, but not zolpidem, is a peripheral benzodiazepine receptor (PBR) ligand, and is also more lipophilic than zolpidem. We compared their effects in isolated rat liver mitochondria and rat hepatocytes. Zolpidem did not affect calcium-induced mitochondrial permeability transition (MPT) in mitochondria, caused little glutathione depletion in hepatocytes, and was not toxic, even at 500 microM. At 250 to 500 microM, alpidem prevented calcium-induced MPT in isolated mitochondria, but caused severe glutathione depletion in hepatocytes that was increased by 3-methylcholanthrene, a cytochrome P4501A inducer, and decreased by cystine, a glutathione precursor. Although cell calcium increased, mitochondrial cytochrome c did not translocate to the cytosol and cells died of necrosis. Cell death was prevented by cystine, but not cyclosporin A, an MPT inhibitor. At low concentrations (25-50 microM), in contrast, alpidem accelerated calcium-induced MPT in mitochondria. It did not deplete glutathione in hepatocytes, but nevertheless caused some cell death that was prevented by cyclosporin A, but not by cystine. Alpidem (10 microM) also increased the toxicity of tumor necrosis factor-alpha (1 ng/ml) in hepatocytes. In conclusion, low concentrations of alpidem increase both calcium-induced MPT in mitochondria, and TNF-alpha toxicity in cells, like other PBR ligands. Like other lipophilic protonatable amines, however, alpidem inhibits calcium-induced MPT at high concentrations. At these high concentrations, toxicity involves cytochrome P4501A-mediated metabolic activation, glutathione depletion, and increased cell calcium, without MPT involvement. In contrast, zolpidem has no mitochondrial effects, causes little glutathione depletion, and is not toxic.
authors.affiliation: INSERM unit 481 and Centre Claude Bernard de Recherches sur les Hépatites Virales, Hôpital Beaujon, Clichy, France. u481@bichat.inserm.fr
authors.forename: A
authors.initials: A
authors.lastname: Berson
authors.forename: V
authors.initials: V
authors.lastname: Descatoire
authors.forename: A
authors.initials: A
authors.lastname: Sutton
authors.forename: D
authors.initials: D
authors.lastname: Fau
authors.forename: B
authors.initials: B
authors.lastname: Maulny
authors.forename: N
authors.initials: N
authors.lastname: Vadrot
authors.forename: G
authors.initials: G
authors.lastname: Feldmann
authors.forename: B
authors.initials: B
authors.lastname: Berthon
authors.forename: T
authors.initials: T
authors.lastname: Tordjmann
authors.forename: D
authors.initials: D
authors.lastname: Pessayre
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D001711:Biotransformation / Q000187:drug effects; D002478:Cells, Cultured; D003574:Cytochrome c Group / Q000378:metabolism; D058785:GABA-A Receptor Agonists; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D007093:Imidazoles / Q000493:pharmacokinetics / Q000633:toxicity*; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000378:metabolism; D010084:Oxidation-Reduction; D010101:Oxygen Consumption / Q000502:physiology; D010539:Permeability; D011725:Pyridines / Q000493:pharmacokinetics / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000187:drug effects*; D000077334:Zolpidem
chemical_list: D014151:Anti-Anxiety Agents; D003574:Cytochrome c Group; D058785:GABA-A Receptor Agonists; D007093:Imidazoles; D011725:Pyridines; D011963:Receptors, GABA-A; D000244:Adenosine Diphosphate; D000077334:Zolpidem; C052036:alpidem